Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, has announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions, as detailed in the company press release.
Cortexyme, Inc. Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, has announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions, as detailed in the company press release. In addition, Cortexyme has granted the underwriters a 30-day option to purchase up to an additional 661,800 shares at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Cortexyme. The offering is expected to close on May 13, 2019, subject to customary closing conditions.
Latham & Watkins LLP advises the underwriters in the initial public offering with a corporate team led by Silicon Valley partner Brian Cuneo and Orange County partner Shayne Kennedy with Orange County associates Ross McAloon and Nicole Jazayeri and Silicon Valley associates Meredith Peake and Nimrah Khan. Advice was also provided on intellectual property matters by Silicon Valley/San Diego partner Christopher Hazuka with San Diego associate Brendan Haberle; on regulatory matters by Washington, D.C. partnersJohn Manthei and Elizabeth Richards with San Francisco counsel Betty Pang and Washington, D.C. associates Barrett Tenbarge and Michael Dreyfuss; on benefits and compensation matters by Silicon Valley partner James Metz with associate James Robinson; and on tax matters by San Francisco partner Grace Lee with Silicon Valley associate Mi Zhou.
